For the period that ended November 15, 2019, the short interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock is on the up. The 13.97% rise could be an indication that investors and traders expect a drop in the share price, often as a result of a drop in the business’ fundamentals. The average brokerage opinion at 2.1 suggests acquiring these shares. Between October 31 and November 15, the total count of shorted shares totalled 17.95 million. That number was 2,199,670 more shares compared with the total of 15.75 million shares in the space of prior two weeks, which suggests more traders or funds are betting that the company stock will move down. The average daily volume for BCRX at the November 15th settlement surged to 3,158,454, versus 1,457,489 at the October 31st report. That led days to cover to move at 5.68293, a 47.41% decrease compared to the 10.805984 days to cover recorded at the prior short interest data release.
On December 03, 2019, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares gained 2.9% or 0.08 points to close at $2.84 with a heavy trading volume of 3.421 million shares. It opened the trading session at $2.73, the shares rose to $2.85 and dropped to $2.655, the range by which the price of stock traded the whole day. The company now has a market cap of $397 million and currently has 139.72 million outstanding shares. BioCryst Pharmaceuticals, Inc. (BCRX) stock has accumulated 37.2 percent of market value in 21 trading days.
BCRX stock’s trailing 3-year beta is 1.98, meaning there will be a greater rate of return, although posing a higher risk. The part of a firm’s profit given to each outstanding share of regular stock was -$1.21 share in the trailing 52 weeks. The stock’s value fallen -64.81 percent year to date (YTD) compared to a decline of -69.06 percent in 52 week’s period. The firm’s shares are still trading -71.46 percent below its 1-year high of $9.95 and 105.8 percent up from 52-week low of $1.38. The average consensus ranking on the company is 2.1, on a ranging where 5 is equal to a consensus sell rating. In other words, the mean analyst recommendations are ranking this stock as a sell.
BioCryst Pharmaceuticals, Inc. (BCRX) is most likely going to rise 151.06 percent in the coming 12 months, as per price target approximations compiled by finviz. Nevertheless, they have set the price target at a $13-month high price target. This represents a whopping 357.75 percent increase from the current trading of shares. The 52-week median price target given by the analysts is $6, which means a return possibility of 111.27 percent in comparison with the closing price of the stock of $2.84 on December 03. The lowest price set for the stock is $4 — just above 40.85 percent from BCRX share price now.
Past records have indicated that shares in BioCryst Pharmaceuticals, Inc. declined on 25 different earnings reaction days and we have yet to see whether this trend will play out and remain in place when the company reports upcoming earnings. Investors will get the next hint of BCRX’s Q4 earnings on February 25. Analysts are predicting revenue to climb 245.9 percent to $9.44M in the financial fourth quarter, while EPS will soar by about 4 percent to -$0.26 per share. In the last quarter, it earnings of -$0.34 per share came worse than the -$0.24327, adjusted, expected by Thomson Reuters consensus estimate. Revenue for the quarter was $2.73M, missing the $3.23M analysts had expected. Earnings are seen to rise by -26 percent this year, 16.4 percent in the coming year and the trend continues by 19.9 percent every year in the next 5 years.
Let’s take a glimpse at some insider activity at BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and observe the pattern. The earliest insider trade happened on 11/18/2019. Babu Yarlagadda S gathered a total of 25 thousand shares of the firm at average share price of $1.45. The total amount for the purchase was set at $36.25 thousand. On completing this exchange, the Senior VP – Drug Discovery account balance was 155.59 thousand shares. The stock grew 90.34 percent from that insider purchase. On 11/18/2019, Barnes Alane P, Senior VP, Chief Legal Officer, did a purchase of 20 thousand shares at a price of $1.45 per share. This increased 29 thousand shares to the insider’s fortune and the stock experienced a 90.34 percent rally in price since the news became public. This exchange saw 102.06 thousand shares get into the Senior VP, Chief Legal Officer account.
On 11/18/2019, Director HEGGIE THERESA recorded a purchase transaction valued at $7.25 thousand. The purchase at $1.45 a share has added 5 thousand shares into the insider’s portfolio position. Meanwhile, shares price witnessed 90.34 percent increase since the transaction reporting date. The company insider is left with 6.67 thousand shares remaining in the account. Hutson Nancy J, who works as Director at the company, performed a purchase of 10 thousand shares in a transaction worth $14.5 thousand. The acquisition recorded on 11/18/2019 was priced at $1.45 per share. The stock price soared 90.34 percent since the transaction. Hutson Nancy J currently holds a stake of 53.05 thousand in BCRX stock which is worth $150.65 thousand after the insider buying.
The stock is lingering around the initial support level of $2.71. After this, the following support is at the zone of $2.59. Up until the time the BCRX stock hit levels beyond the current one, bulls should have no alarm. In terms of its momentum, the stock’s RSI hit 66.33 on the daily chart, and this may be a cause for concern. In case the price goes below $2.59 level on closing basis, there may be more profit booking with the stock growing weaker. Still, getting to the $2.91 level may cause a pull-back move approaching $2.98 mark.
BioCryst Pharmaceuticals, Inc. has a 86.5% gross profit margin.